1. Harreiter J, Roden M. Diabetes mellitus: definition, classification, diagnosis, screening and prevention (Update 2023). Wien Klin Wochenschr 2023;135(Suppl 1):7-17. http://dx.doi.org/10.1007/s00508-022-02122-y. [DOI:10.1007/s00508-022-02122-y] [PMID] []

2. Taheri S, Saffaei A, Amani B, Akbarzadeh A, Peiravian F, Yousefi N. Efficacy and safety of dulaglutide compared to liraglutide: A systematic review and meta-analysis in patients with type 2 diabetes mellitus. Iran J Pharm Res 2019 Autumn;18(4):2180-90. http://dx.doi.org/10.22037/ijpr.2019.14733.12619. [] [PMID]

3. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 2018;14(2):88-98. http://dx.doi.org/10.1038/nrendo.2017.151. [DOI:10.1038/nrendo.2017.151] [PMID]

4. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94(3):311-21. http://dx.doi.org/10.1016/j.diabres.2011.10.029. [DOI:10.1016/j.diabres.2011.10.029] [PMID]

5. Ashrafi Z P. Evaluation of quality of life among diabetic patients (type II) referring to Tehran Imam Khomeini Hospital in the summer of 2012. Knowledge and health. 2015;10(1):58-63. [Google Scholar]

6. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287(19):2570-81. http://dx.doi.org/10.1001/jama.287.19.2570. [DOI:10.1001/jama.287.19.2570] [PMID]

7. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Spectr 2012;25(3):154-71. http://dx.doi.org/10.2337/diaspect.25.3.154. [DOI:10.2337/diaspect.25.3.154]

8. Wilkinson A, Whitehead L, Ritchie L. Factors influencing the ability to self-manage diabetes for adults living with type 1 or 2 diabetes. Int J Nurs Stud 2014;51(1):111-22. http://dx.doi.org/10.1016/j.ijnurstu.2013.01.006. [DOI:10.1016/j.ijnurstu.2013.01.006] [PMID]

9. Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, Del Cañizo-Gómez FJ. Update on the treatment of type 2 diabetes mellitus. World J Diabetes 2016;7(17):354-95. http://dx.doi.org/10.4239/wjd.v7.i17.354. [DOI:10.4239/wjd.v7.i17.354] [PMID] []

10. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321(7258):405-12. http://dx.doi.org/10.1136/bmj.321.7258.405. [DOI:10.1136/bmj.321.7258.405] [PMID] []

11. Blonde L. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleve Clin J Med 2009;76 Suppl 5(12 suppl 5):S4-11. http://dx.doi.org/10.3949/ccjm.76.s5.02. [DOI:10.3949/ccjm.76.s5.02] [PMID]

12. Hayes J, Anderson R, Stephens JW. Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. Drug design. development and therapy. 2016;10:2263-70. [DOI:10.2147/DDDT.S93076] [PMID] []

13. Green J, Feinglos M. New combination treatments in the management of diabetes: focus on sitagliptin-metformin. Vasc Health Risk Manag 2008;4(4):743-51. http://dx.doi.org/10.2147/vhrm.s3105. [DOI:10.2147/VHRM.S3105] [PMID] []

14. Weissman P, Goldstein BJ, Rosenstock J, Waterhouse B, Cobitz AR, Wooddell MJ, et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin 2005;21(12):2029-35. http://dx.doi.org/10.1185/030079905x74844. [DOI:10.1185/030079905X74844] [PMID]

15. Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults: a consensus report. J Am Geriatr Soc 2012;60(12):2342-56. http://dx.doi.org/10.1111/jgs.12035. [DOI:10.1111/jgs.12035] [PMID] []

16. Bhosle DS, Bhagat AH, Patil AD, Bobde JA, Bhagat AA. Effects of a fixed-dose combination of sitagliptin and metformin versus respective monotherapies in newly diagnosed type 2 diabetic subjects. Int J Diabetes Dev Ctries 2017;37(1):16-20. http://dx.doi.org/10.1007/s13410-015-0370-8. [DOI:10.1007/s13410-015-0370-8]

17. Derosa G, Carbone A, D'Angelo A, Querci F, Fogari E, Cicero AFG, et al. Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin. Intern Med 2013;52(19):2179-87. http://dx.doi.org/10.2169/internalmedicine.52.8175. [DOI:10.2169/internalmedicine.52.8175] [PMID]

18. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30(8):1979-87. http://dx.doi.org/10.2337/dc07-0627. [DOI:10.2337/dc07-0627] [PMID]

19. Herman GA, Bergman A, Yi B, Kipnes M, Sitagliptin Study 012 Group. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin 2006;22(10):1939-47. http://dx.doi.org/10.1185/030079906X132587. [DOI:10.1185/030079906X132587] [PMID]

20. Ji L, Han P, Wang X, Liu J, Zheng S, Jou YM, et al. Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus. J Diabetes Investig 2016;7(5):727-36. http://dx.doi.org/10.1111/jdi.12511. [DOI:10.1111/jdi.12511] [PMID] []

21. Olansky L, Reasner C, Seck TL, Williams-Herman DE, Chen M, Terranella L, et al. A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents. Diabetes Obes Metab 2011;13(9):841-9. http://dx.doi.org/10.1111/j.1463-1326.2011.01416.x. [DOI:10.1111/j.1463-1326.2011.01416.x] [PMID]

22. Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008;24(2):537-50. http://dx.doi.org/10.1185/030079908x260925. [DOI:10.1185/030079908X260925] [PMID]

23. Reasner C, Olansky L, Seck TL, Williams-Herman DE, Chen M, Terranella L, et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011;13(7):644-52. http://dx.doi.org/10.1111/j.1463-1326.2011.01390.x. [DOI:10.1111/j.1463-1326.2011.01390.x] [PMID]

24. Yang W, Guan Y, Shentu Y, Li Z, Johnson-Levonas AO, Engel SS, et al. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes: Sitagliptin + metformin in Chinese patients. J Diabetes 2012;4(3):227-37. http://dx.doi.org/10.1111/j.1753-0407.2012.00213.x. [DOI:10.1111/j.1753-0407.2012.00213.x] [PMID]

25. Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab 2012;38(2):89-101. http://dx.doi.org/10.1016/j.diabet.2011.11.001. [DOI:10.1016/j.diabet.2011.11.001] [PMID]

26. Du Q, Wu B, Wang YJ, Yang S, Zhao YY, Liang YY. Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis. Curr Med Res Opin 2013;29(11):1487-94. http://dx.doi.org/10.1185/03007995.2013.833090. [DOI:10.1185/03007995.2013.833090] [PMID]

27. Li M, Yang Y, Jiang D, Ying M, Wang Y, Zhao R. Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis: A systematic review and meta-analysis. Medicine (Baltimore) 2017;96(39):e8161. http://dx.doi.org/10.1097/MD.0000000000008161 [DOI:10.1097/MD.0000000000008161] [PMID] []

28. Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes. Obesity and Metabolism. 2014;16(1):30-7. [DOI:10.1111/dom.12174] [PMID]

29. Ji M, Xia L, Cao J, Zou D. Sitagliptin/metformin versus insulin glargine combined with metformin in obese subjects with newly diagnosed type 2 diabetes. Medicine (Baltimore) 2016;95(11):e2961. http://dx.doi.org/10.1097/MD.0000000000002961.30. Lu J, Zang J, Li H. Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis. PLoS One 2013;8(10):e76713. http://dx.doi.org/10.1371/journal.pone.0076713. [DOI:10.1371/journal.pone.0076713] [PMID] []

30. Papanas N, Maltezos E. Metformin: A review of its use in the treatment of type 2 diabetes. Clin Med Ther 2009;1:CMT.S1085. http://dx.doi.org/10.4137/cmt.s1085. [DOI:10.4137/CMT.S1085]

31. Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 2014;348(apr15 2):g2366. http://dx.doi.org/10.1136/bmj.g2366. [DOI:10.1136/bmj.g2366] [PMID] []

32. Ballav C, Gough SCL. Safety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitus. Clin Med Insights Endocrinol Diabetes 2013;6:25-37. http://dx.doi.org/10.4137/CMED.S7314 [DOI:10.4137/CMED.S7314] [PMID] []